Disability Levels and Cognitive Functioning Reported by Patients Impaired by Gentamicin and Other Aminoglycosides

Ann M. Kerlin

SAGE Open, 2017, vol. 7, issue 2, 2158244017709323

Abstract: The purpose of this study was to explore disability levels and cognitive functioning in patients who reported being damaged by aminoglycosides, a class of antibiotic drugs. An online questionnaire was published using the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) and the NeuroQol Cognitive Functioning v.2. Gentamicin was the most frequent cause of impairment in patients, and the overall disability level was moderate (46.05%). Severe impairments were reported in mobility (Getting Around: 53.67%), Life Activities (60.20%), and Participation in Society (55.19%), and the NeuroQol Cognitive Function measure was approximately 1 standard deviation below normal. Participants who reported impairment from gentamicin and other aminoglycosides indicate a diminished quality of life, along with accompanying depression and anxiety.

Keywords: aminoglycosides; disability; cognitive impairment; WHODAS 2.0; gentamicin (search for similar items in EconPapers)
Date: 2017
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.sagepub.com/doi/10.1177/2158244017709323 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:sae:sagope:v:7:y:2017:i:2:p:2158244017709323

DOI: 10.1177/2158244017709323

Access Statistics for this article

More articles in SAGE Open
Bibliographic data for series maintained by SAGE Publications ().